Explore 3 Stock Ideas & Industry Insights Download Free Report

Jade Biosciences, Inc.

Company price
15.33 USD 0.27 ( 1.79%)
Last update at 2026-11-20T15:24:00Z
VOLUME
65947
Market Cap
1105.32M

Momentum Score

…

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
15.00
Low
15.46
High
52 Week Price Range
7.00
Low
28.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Jade Biosciences, Inc. (NASDAQ: JBIO) is limited; filings identify it as a biotechnology firm but provide few operational details. Long-term growth depends on progressing any therapeutic pipeline through clinical trials, obtaining regulatory approvals, and securing commercial partnerships or funding, which may benefit shareholders if achieved. Investors may see early-stage upside from clinical milestones, though outcomes are uncertain.

Material risks include sparse public disclosure, clinical and regulatory failure, dependence on external financing, potential dilution, and low stock liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
15.06
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-89.19%
Net Debt
-87.71M
ROCE
-38.22%
Diluted EPS TTM
-1.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -127.35M -69.57M -75.47M -51.49M -22.96M
Net income -127.41M -69.63M -75.52M -51.51M -22.96M
Selling general administrative 20.22M 0.01M - - -
Selling and marketing expenses 0.20M - - - -
Gross profit -0.03M -0.28M -0.10M -0.07M -0.01M
Reconciled depreciation 0.03M - - - -
Ebit -127.35M -69.57M -75.47M -51.49M -22.96M
Ebitda -127.33M -69.29M -75.37M -51.42M -22.95M
Depreciation and amortization 0.03M 0.28M 0.10M 0.07M 0.01M
Operating income -113.54M -74.60M -81.41M -53.24M -23.02M
Other operating expenses 113.54M 74.60M 81.41M 53.24M 23.02M
Tax provision 0.06M - - - -
Interest income 7.78M - - - -
Net interest income 7.78M - - - -
Income tax expense 0.06M 0.06M 0.06M 0.03M 0.00M
Total revenue 0.00M - - - -
Total operating expenses 113.54M 74.31M 81.31M 53.17M 23.01M
Cost of revenue 0.03M 0.28M 0.10M 0.07M 0.01M
Total other income expense net -13.81M 5.02M 5.94M 1.75M 0.06M
Net income from continuing ops -127.41M - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 349.78M 80.33M 127.42M 135.30M 175.36M
Other current assets 12.66M 1.49M 1.79M 2.28M 6.96M
Total liab 17.26M 3.90M 17.96M 8.56M 2.94M
Total stockholder equity 332.52M 76.43M 109.46M 126.74M 172.42M
Other current liab 14.39M 3.19M 14.82M 4.82M 1.15M
Common stock 0.01M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.00M - - -
Retained earnings -174.39M -233.05M -163.42M -87.90M -36.39M
Cash 88.44M 33.75M 23.49M 22.40M 54.20M
Total current liabilities 16.54M 3.83M 17.64M 7.78M 2.55M
Net debt -87.71M -33.33M -22.82M -21.31M -53.62M
Short term debt - 0.42M 0.42M 0.39M 0.19M
Short long term debt total 0.72M 0.42M 0.68M 1.09M 0.57M
Other stockholder equity 506.77M 309.38M 272.64M 215.11M 208.87M
Total current assets 336.16M 80.12M 124.23M 131.50M 174.33M
Short term investments 247.72M 44.87M 98.95M 106.82M 113.18M
Long term debt - 107.60M - - -
Accounts payable 2.15M 0.22M 2.40M 2.58M 1.21M
Accumulated other comprehensive income 0.13M 0.10M 0.24M -0.47M -0.06M
Non currrent assets other 13.62M -0.21M 2.28M 2.56M 0.30M
Non current assets total 13.62M 0.21M 3.19M 3.80M 1.03M
Capital lease obligations 0.72M 0.00M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -246.78M - - - -
Total cashflows from investing activities -247.01M 56.03M 11.88M 6.93M -113.43M
Net borrowings 0.00M - - - -
Total cash from financing activities 360.77M 25.43M 46.00M 0.40M 190.46M
Net income -127.41M -69.63M -75.52M -51.51M -22.96M
Change in cash 19.05M 10.26M 1.09M -31.80M 49.62M
Begin period cash flow 69.39M 23.49M 22.40M 54.20M 4.57M
End period cash flow 88.44M 33.75M 23.49M 22.40M 54.20M
Total cash from operating activities -94.69M -71.20M -56.78M -39.12M -27.40M
Issuance of capital stock 189.11M - - - -
Depreciation 0.03M 0.28M 0.10M 0.07M 0.01M
Other cashflows from investing activities -0.03M - - - -
Other cashflows from financing activities 171.27M 0.18M - - -
Capital expenditures 0.20M 0.00M 0.14M 0.20M 0.18M
Change in working capital -8.20M -11.17M 9.80M 7.75M -6.51M
Stock based compensation 20.01M 0.00M - - -
Other non cash items 20.88M 9.32M 8.85M 4.57M 2.06M
Free cash flow -94.89M -71.20M -56.92M -39.32M -27.58M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
JBIO
Jade Biosciences, Inc.
0.27
1.79%
15.33 - - - 2.63
NVO
Novo Nordisk A/S
0.04
0.09%
38.91 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc
5.97
1.15%
526.63 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc
9.17
0.99%
932.51 29.07 20.12 7.57 3.82
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12

Profile*

Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Building 23, Waltham, MA, United States, 02453

781 312 3013

55

Name Title Year Born
Mr. Tom Frohlich President, CEO & Director 1976
Mr. Bradford D. Dahms Ph.D. CFO & Treasurer 1989
Dr. Andrew James King BVMS, D.V.M., Ph.D. President of Research & Development 1980
Ms. Elizabeth Balta J.D. Chief Legal Officer & Corporate Secretary 1971
Ms. Lori Stewart Senior Vice President of People NA
Mr. Jonathan Quick Senior Vice President of Finance NA
Ms. Valerie Fauvelle Senior Vice President of Regulatory & Quality NA
Ms. Amy Sullivan Senior Vice President of Development Operations NA
Ms. Sandy Lewis Senior Vice President, Biometrics & Clinical Strategy NA
Dr. Edward R. Conner M.D. Chief Medical Officer 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…